Relmada Therapeutics (RLMD) Misses Q3 EPS by 4c

Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($0.72), $0.04 worse than the analyst estimate of ($0.68).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Former Fed Chair Alan Greenspan dies at 100
• Labcorp makes RNA-based colorectal cancer home test available nationwide
• Qtrex Quantum executives plan to buy up to 2M shares over 12 months